Three further groups were treated with trastuzumab, an antibody against HER2, as well as AMD3100 and CTCE9908, two inhibitors of CXCR4 that have been shown to be involved in migration and tumour cell homing in esophageal carcinoma. Here, ERBB2 is linked to neoplasm.